Inventiva signs over China NASH rights to Sino Biopharm in possible $300M+ deal
More than two years after claiming a Phase II win in one of the most challenging diseases faced in biotech, Inventiva is handing over rights in several Asian markets to a more on-site company.
Inventiva and Sino Biopharm jointly announced the deal Wednesday after market close, where Inventiva will hand over development and commercialization rights for NASH candidate lanifibranor to Sino Biopharm subsidiary Chia Tai-Tianqing Pharmaceutical Group (CTTQ). Rights include those in China, Hong Kong, Macau and Taiwan.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.